The role of methotrexate in osteosarcoma

Jean L. Grem, Susan A. King, Robert E. Wittes, Brian Leyland-jones

Research output: Contribution to journalReview article

37 Citations (Scopus)

Abstract

High-dose methotrexate (MTX) is one of the agents currently used in intensive adjuvant chemotherapy regimens for nonmetastatic osteosarcoma. To elucidate the role of high-dose MTX in this disease, we present the history of trials conducted with MTX from the first single-agent studies through progressively complex combination regimens. With this background, some of the basic dissues concerning MTX therapy in osteosarcoma are discussed. [J Natl Cancer Inst 1988;80:626-656].

Original languageEnglish (US)
Pages (from-to)626-655
Number of pages30
JournalJournal of the National Cancer Institute
Volume80
Issue number9
DOIs
StatePublished - Jul 6 1988

Fingerprint

Osteosarcoma
Methotrexate
Adjuvant Chemotherapy
History
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

The role of methotrexate in osteosarcoma. / Grem, Jean L.; King, Susan A.; Wittes, Robert E.; Leyland-jones, Brian.

In: Journal of the National Cancer Institute, Vol. 80, No. 9, 06.07.1988, p. 626-655.

Research output: Contribution to journalReview article

Grem, Jean L. ; King, Susan A. ; Wittes, Robert E. ; Leyland-jones, Brian. / The role of methotrexate in osteosarcoma. In: Journal of the National Cancer Institute. 1988 ; Vol. 80, No. 9. pp. 626-655.
@article{66a16eddcdda41c5a22eeb9bd675cf99,
title = "The role of methotrexate in osteosarcoma",
abstract = "High-dose methotrexate (MTX) is one of the agents currently used in intensive adjuvant chemotherapy regimens for nonmetastatic osteosarcoma. To elucidate the role of high-dose MTX in this disease, we present the history of trials conducted with MTX from the first single-agent studies through progressively complex combination regimens. With this background, some of the basic dissues concerning MTX therapy in osteosarcoma are discussed. [J Natl Cancer Inst 1988;80:626-656].",
author = "Grem, {Jean L.} and King, {Susan A.} and Wittes, {Robert E.} and Brian Leyland-jones",
year = "1988",
month = "7",
day = "6",
doi = "10.1093/jnci/80.9.626",
language = "English (US)",
volume = "80",
pages = "626--655",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "9",

}

TY - JOUR

T1 - The role of methotrexate in osteosarcoma

AU - Grem, Jean L.

AU - King, Susan A.

AU - Wittes, Robert E.

AU - Leyland-jones, Brian

PY - 1988/7/6

Y1 - 1988/7/6

N2 - High-dose methotrexate (MTX) is one of the agents currently used in intensive adjuvant chemotherapy regimens for nonmetastatic osteosarcoma. To elucidate the role of high-dose MTX in this disease, we present the history of trials conducted with MTX from the first single-agent studies through progressively complex combination regimens. With this background, some of the basic dissues concerning MTX therapy in osteosarcoma are discussed. [J Natl Cancer Inst 1988;80:626-656].

AB - High-dose methotrexate (MTX) is one of the agents currently used in intensive adjuvant chemotherapy regimens for nonmetastatic osteosarcoma. To elucidate the role of high-dose MTX in this disease, we present the history of trials conducted with MTX from the first single-agent studies through progressively complex combination regimens. With this background, some of the basic dissues concerning MTX therapy in osteosarcoma are discussed. [J Natl Cancer Inst 1988;80:626-656].

UR - http://www.scopus.com/inward/record.url?scp=0023946811&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023946811&partnerID=8YFLogxK

U2 - 10.1093/jnci/80.9.626

DO - 10.1093/jnci/80.9.626

M3 - Review article

C2 - 3286880

AN - SCOPUS:0023946811

VL - 80

SP - 626

EP - 655

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 9

ER -